Publications by authors named "Luna S Hansen"
Article Synopsis
- Light-based gamma entrainment using sensory stimuli (GENUS) shows promise as a treatment for Alzheimer's disease (AD), but the discomfort from flickering lights may hinder patient adherence to the therapy.
- A study investigates Invisible spectral flicker (ISF), which is a less detectable type of flicker, and finds it significantly more comfortable and less distracting for users compared to traditional luminance flickering (LF).
- While reducing brightness didn’t impact SSVEP responses, it improved comfort, suggesting that combining ISF with less direct stimulation could enhance the overall treatment experience for AD patients.
Background: Major depressive disorder (MDD) is a debilitating condition that affects more than 300 million people worldwide. Current treatments are based on a trial-and-error approach, and reliable biomarkers are needed for more informed and personalized treatment solutions. One of the potential biomarkers, gamma-frequency (30-80 Hz) brainwaves, are hypothesized to originate from the excitatory-inhibitory interaction between the pyramidal cells and interneurons.
View Article and Find Full Text PDFBackground: Exposure to 40 Hz stroboscopic light, for one hour a day, has previously been published as a potential treatment option for Alzheimer's disease in animal models. However, exposure for an hour a day to 40 Hz stroboscopic light can be strenuous and examining other types of 40 Hz inducing stimuli is paramount if chronic treatment is wanted.
Objective: A core assumption behind ensuring a therapeutic outcome is that the visual stimuli can induce 40 Hz gamma entrainment.